Cargando…
Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
BACKGROUND: Omalizumab has been approved for treating moderate-to-severe asthma in children aged over 6 years. Its application to asthmatic children with other allergic diseases has been rarely explored. The present study aims to explore the therapeutic efficacy of omalizumab in children with modera...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613665/ https://www.ncbi.nlm.nih.gov/pubmed/37908372 http://dx.doi.org/10.3389/falgy.2023.1236798 |